References for Spring Worcester Medicine

Innovations in Education and Training to Improve Perinatal Mental Health by Martha Zimmermann, PhD; Anna R. Whelan, MD, FACOG; Tiffany A. Moore Simas, MD, MPH, MEd, FACOG; and Nancy Byatt, DO, MS, MBA, DFAPA, FACLP

[1]        S. Trost et al., “Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 States, 2017-2019,” Education, vol. 45, no. 10, pp. 1-0, 2022.

[2]        K. B. Kozhimannil, C. M. Trinacty, A. B. Busch, H. A. Huskamp, and A. S. Adams, “Racial and ethnic disparities in postpartum depression care among low-income women,” (in eng), Psychiatr Serv, vol. 62, no. 6, pp. 619-25, Jun 2011, doi: 62/6/619 [pii]


[3]        “Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4,” (in eng), Obstet Gynecol, vol. 141, no. 6, pp. 1232-1261, Jun 1 2023, doi: 10.1097/aog.0000000000005200.

[4]        “Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum No. 5,” Obstet Gynecol, vol. 141, no. 6, pp. 1262-1288, 2023.

[5]        N. Byatt et al., “Effectiveness of two systems-level interventions to address perinatal depression in obstetric settings (PRISM): an active-controlled cluster-randomised trial,” The Lancet Public Health, vol. 9, no. 1, pp. e35-e46, 2024.




The Black Maternal Health Crisis, Black Women are Not Broken by Cherise Hamblin, MD and Ahnyia Sanders, MS:

[1] Organization for Economic Co-Operation and Development (2023, July 3). Health Status: Maternal and infant mortality. OCED.Stat. Retrieved October 26, 2023, from

[2] Hoyert, D. L. (2023). Maternal Mortality Rates in the United States, 2021. National Center for Health Statistics. Retrieved October 26, 2023, from

[3] Hoyert, D. L. (2023). Maternal Mortality Rates in the United States, 2021. National Center for Health Statistics. Retrieved October 26, 2023, from

[4] Commonwealth of Massachusetts Department of Public Health (2023, July 1). Data Brief: An Assessment of Severe Maternal Morbidity in Massachusetts: 2011-2020. Retrieved October 26, 2023, from

[5] What is a doula. DONA International. (2023, June 23).

[6] Sobczak, A., Taylor, L., Solomon, S., Ho, J., Kemper, S., Phillips, B., Jacobson, K., Castellano, C., Ring, A., Castellano, B., & Jacobs, R. J. (2023). The Effect of Doulas on Maternal and Birth Outcomes: A Scoping Review. Cureus, 15(5), e39451.

[7] Ehrenreich, B. (2010). Witches, Midwives, & Nurses (Second Edition) : A History of Women Healers, The Feminist Press at CUNY, 2010. ProQuest Ebook Central.



[10] American Medical Association. AMA Physician Masterfile (Dec. 31, 2021). Race and ethnicity are obtained from a variety of AAMC sources, including DBS, ERAS, APP, MCAT, SMDEP, GQ, MSQ, PMQ, FACULTY, GME, and STUDENT, with priority given to the most recent self-reported source.



Misinformation and Manipulation: Exposing Crisis Pregnancy Centers by Zarah Rosen, MD:

  1. Raymond EG, Grimes DA. The comparative safety of legal Induced abortion and childbirth in the United States. Obstetrics and Gynecology. 2012;119(2 Pt 1):215-219. doi:
  2. Committee on Gynecologic Practice. Committee opinion: Induced abortion and breast cancer risk. 434. The American College of Obstetricians and Gynecologists. 2009. Accessed January 1, 2024.
  3. Abortion access fact sheet. The American College of Obstetricians and Gynecologists. Accessed January 1, 2024.
  4. Abortion and cancer risk. American Cancer Society. Accessed January 1, 2024.
  5. Abortion risks. National Health Service (UK). Accessed January 1, 2024.
  6. Bixby Center for Global Reproductive Health. Introduction to the turnaway study chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/ Published 2022. Accessed January 1, 2024.
  7. Find abortion care in Massachusetts. Reproductive Equity Now. Accessed December 30, 2023.
  8. Swartzendruber A and Lambert D. Crisis pregnancy center map. Published August, 2021. Accessed: December 30, 2023.



Promoting the Health, Inclusion, and Belonging of Sexual and Gender Minorities in the Clinical Space by Olivia Buckle, BA:

Center, N. L. H. E. (2021). Ten Strategies for Creating Inclusive Health Care Environments for LGBTQIA+ People (2021). T. F. Institute., The Fenway Institute.

Dahlen, S., et al. (2021). “International clinical practice guidelines for gender minority/trans people: systematic review and quality assessment.” BMJ Open 11(4): e048943.

James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). Executive Summary of the Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality.


Pharmacological Advancements for Women’s Reproductive Health Transitions by Mary Fischer, PhD, WHNP-BC, MSCP, Audrey O’Neil, RN, David Runyan, FNP-BC, NRP, and Teri Aronowitz, PhD, FNP-BC, FAAN

  1. Hoyt, L.T. & Falconi, A.M. (2015). Puberty and perimenopause: Reproductive transitions and their implications for women’s health. Social Science & Medicine, 132, 103-113.
  2. Santoro, N., Roeca, C., Peters, B. A., & Neal-Perry, G. (2021). The Menopause Transition: Signs, Symptoms, and Management Options. The Journal of Clinical Endocrinology & Metabolism, 106 (1), 1- 15.
  3. Pearlstein, T., Howard, M., Salisbury, A., & Zlotnick, C. (2009) Postpartum depression. American Journal of Obstetrics and Gynecology, 200(4): 357-64.
  4. De Baetselier, E., Dilles, T., Feyen, H., Haegdorens, F., Mortelmans, L., & Van Rompaey, B. (2022). Nurses’ responsibilities and tasks in pharmaceutical care: A scoping review. Nursing open, 9(6), 2562–2571.
  5. Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., Rana, N., Garcia, M., Leclair, B., & Doherty, J. (2023). Zuranolone for the Treatment of Postpartum Depression. The American journal of psychiatry, 180(9), 668–675.
  6. Ghaedrahmati M., Kazemi, A., Kheirabadi, G., Ebrahimi, A., & Bahrami, M. (2017) Postpartum depression risk factors: A narrative review. Journal of Education and Health Promotion, (6) 60. DOI:10.4103/jehp.jehp_9_16
  7. Chin, K., Wendt, A., Bennett, I. M., & Bhat, A. (2022) Suicide and Maternal Mortality. Current Psychiatry Reports, 24(4):239-275.
  8. Suryawanshi, O., 4th, & Pajai, S. (2022) A Comprehensive Review on Postpartum Depression. Cureus. 14(12):e32745.
  9. Aschenbrenner, D. (2023). First Oral Treatment for Postpartum Depression. AJN The American Journal of Nursing, 123(12), 16-17.
  10. Moore Simas TA, Whelan A, Byatt N. (2023). Postpartum Depression—New Screening Recommendations and Treatments. JAMA, 330(23):2295–2296. Https://
  11. Beninger, P. (2023). Zuranolone. Clinical therapeutics, 45(12), 1297-1298.
  12. Talaulikar, V. (2022). Menopause transition: Physiology and symptoms. Best Practice & Research Clinical Obstetrics & Gynaecology, 81, 3–7.
  13. Avis, N. E., Crawford, S. L., & Green, R. (2018). Vasomotor symptoms across the menopause transition. Obstetrics and Gynecology Clinics of North America, 45(4), 629–640.
  14. Patel, B., & Dhillo, W. S. (2022). Menopause review: Emerging treatments for menopausal symptoms. Best Practice & Research Clinical Obstetrics & Gynaecology, 81, 134-144.
  15. Conklin, M., & Santoro, N. (2023). Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause. Therapeutic Advances in Reproductive Health, 17, 1-8.
  16. Christ, J. P., Navarro, V. M., & Reed, S. D. (2023). Nonhormonal Therapies for Menopausal Vasomotor Symptoms. JAMA, 330(13), 1278-1279.
  17. Shufelt, C. L., Brown, V., Carpenter, J. S., Chism, L. A., Faubion, S. S., Joffe, H., Kling, J. M., Soares, C., & Thurston, R. C. (2023) The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590.
  18. Javernick, J. A. (2023). A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause. Nursing for Women’s Health.
  19. Mirin, A.A. (2021). Gender disparity in the funding of diseases by the U.S. National Institutes of Health. Journal of Women’s Health, 30(7), 956-963.



New Innovations to Increase Contraception Access in Massachusetts by Katharine Nault, PharmD, MBA, BCCCP and Aimee Dawson, PharmD:


  1. FDA approves First Nonprescription Daily Oral Contraceptive. (2023, July 13). U.S. FDA.
  2. FDA Briefing Document: Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee. (2023, May).
  3. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-3). 10.15585/mmwr.rr6503a1.
  4. Progestin-Only Hormonal Birth Control: Pill and Injection. (2023, January). ACOG.
  5. OPill FAQs. Perrigo.
  6. Webb JL. Nutritional effects of oral contraceptive use: a review. J Reprod Med. 1980;25(4):150-156.
  7. FDA allows marketing of first DTC app for contraceptive use to prevent pregnancy. (2018, August 10) U.S. FDA.
  8. Lavery, JG. Circular Letter: DCP 23-10-121. (2023, November 1) DPH.,self%2Dadministered%20oral%20hormonal%20contraceptives